December 1998
Clinical & Investigative Medicine;Dec98 Supplement, Vol. 21, pS43
Academic Journal
The article presents various studies related to hematology. These studies include the use of outpatient low molecular weight heparin in the treatment of deep vein thrombosis of the upper extremity, donor leukocyte infusion which induces long-term molecular remission and therapeutic leukapheresis for hyperleukocytosis in acute myeloid leukemia.


Related Articles

  • Emergency therapeutic leukapheresis in a case of acute myeloid leukemia M5. Ranganathan, Sudha; Sesikeran, Shyamala; Gupta, Vineet; Vanajakshi // Asian Journal of Transfusion Science;Jan-Jun2008, Vol. 2 Issue 1, p18 

    Cell separators in India are routinely used for plateletpheresis, peripheral blood stem cell collections and therapeutic plasma exchange. Therapeutic leukapheresis, particularly as an emergency procedure, has been uncommonly performed and reported. Here, a case of a 53-year-old male, diagnosed...

  • Assessment of monocytic component in acute myelomonocytic and monocytic/monoblastic leukemias by a chemiluminescent assay. da Fonseca, Luiz M; Brunetti, Iguatemy L; Campa, Ana; Catalani, Luiz H; Calado, Rodrigo T; Falcao, Roberto P // Hematology Journal;2003, Vol. 4 Issue 1, p26 

    INTRODUCTION:: Classically, the monocytic component of acute myelomonocytic (FAB-M4) and acute monocytic/monoblastic (FAB-M5) leukemias is demonstrated by nonspecific esterase positivity in cytochemical stainings. We have previously demonstrated that non-specific esterases from normal monocytes...

  • Induction of graft-versus-leukemia to prevent relapse after partially lymphocyte-depleted allogeneic bone marrow transplantation by pre-emptive donor leukocyte infusions. Schaap, N; Schattenberg, A; Bär, B; Preijers, F; van de Wiel van Kemenade, E; de Witte, T // Leukemia (08876924);Sep2001, Vol. 15 Issue 9, p1339 

    In this prospective study we analyzed pre-emptive donor leukocyte infusions (DLI) in 82 consecutive patients transplanted with partially T cell-depleted grafts for acute myeloid leukemia, acute lymphoid leukemia, chronic myeloid leukemia, refractory anemia with excess of blasts, refractory...

  • Long survival in acute myelogenous leukaemia: an international collaborative study. Whittaker, J.A.; Reizenstein, P.; Callender, Sheila T.; Cornwell, G.G.; Delamore, I.W.; Gale, R.P.; Gobbi, M.; Jacobs, P.; Lantz, B.; Maiolo, A.T.; Rees, J.K.H.; Van Slyck, E.J.; Vu Van, H. // British Medical Journal (Clinical Research Edition);2/28/1981, Vol. 282 Issue 6265, p692 

    Examines long-term survivors of acute myelogenous leukemia. Assessment of immunotherapy; Measurement of bone or marrow myeloblasts; Reduction in total white cell and granulocyte counts.

  • Publication Only (Abstracts 841-861).  // Hematology Journal;2004 Supplement 2, Vol. 5, pS279 

    Presents abstracts of studies on hematology. Atrovastatin modifies the expression of both endothelium- and liver-derived components of thrombosis/fibrinolysis system during the acute phase of unstable angina; Prognostic relevance of CD33/HLA DR expression in acute myeloid leukemia patients;...

  • Population Pharmacokinetics of an Anti-PD-L1 Antibody, Durvalumab in Patients with Hematologic Malignancies. Ogasawara, Ken; Newhall, Kathryn; Maxwell, Stephen E.; Dell'Aringa, Justine; Komashko, Vitalina; Kilavuz, Nurgul; Delarue, Richard; Czuczman, Myron; Sternas, Lars; Rose, Shelonitda; Beach, C. L.; Novick, Steven; Zhou, Simon; Palmisano, Maria; Li, Yan // Clinical Pharmacokinetics;Feb2020, Vol. 59 Issue 2, p217 

    Background and Objectives: Durvalumab, a human monoclonal antibody targeting programmed cell death ligand 1, has been approved for urothelial carcinoma and stage III non-small cell lung cancer by the US Food and Drug Administration and is being evaluated in various malignancies. The...

  • Prognostic significance of FLT3 ITD and D835 mutations in AML patients. Sheikhha, Mohammad Hasan; Awan, Abida; Tobal, Khalid; Liu Yin, John Ahman // Hematology Journal;2003, Vol. 4 Issue 1, p41 

    Both ITD and D835 mutations of the fms-like tyrosine kinase (FLT3) gene cause constitutive activation of the receptor, in the absence of ligand. We have examined a cohort of 91 patients, AML (80) and MDS (11), to determine the prevalence of these mutations and any correlations between the two...

  • IN BRIEF.  // Hem/Onc Today;12/25/2008, Vol. 9 Issue 23, p25 

    The article presents updates on hematology and oncology. According to a univariate analysis, there is a non-significant cost savings with enoxaparin venous thromboembolism (VTE) prophylaxis. According to a clinical trial, decitabine active in older patients with previously untreated acute...

  • Cytogenetic profile of de novo acute myeloid leukemia: a study based on 1432 patients in a single institution of China. Cheng, Y.; Wang, Y.; Wang, H.; Chen, Z.; Lou, J.; Xu, H.; Wand1,2, H.; Qian, W.; Meng, H.; Lin, M.; Jin, J. // Leukemia (08876924);Oct2009, Vol. 23 Issue 10, p1801 

    Geographic heterogeneity of cytogenetic patterns in hematological malignancies has been reported earlier, but few systematic studies of cytogenetic abnormalities in acute myeloid leukemia (AML) patients are available. We examined the karyotypic patterns in 1432 de novo AML patients from a single...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics